1. US Food and Drug Administration. Guidance for industry and investigators: safety reporting requirements for INDs and BA/BE (bioavailability/bioequivalence) studies. 2012. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-reporting-requirements-inds-investigational-new-drug-applications-and-babe. Accessed 27 June 2023.
2. Sasseville VG, Mansfield KG, Brees DJ. Safety biomarkers in preclinical development: translational potential. Vet Pathol. 2014;51:281–91.
3. Yu J, Ritchie TK, Zhou Z, Ragueneau-Majlessi I. Key findings from preclinical and clinical drug interaction studies presented in new drug and biological license applications approved by the Food and Drug Administration in 2014. Drug Metab Dispos. 2016;44:83–101.
4. US Food and Drug Administration. Guidance for clinical trial sponsors: establishment and operation of clinical trial data monitoring committees. 2006. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishment-and-operation-clinical-trial-data-monitoring-committees. Accessed 13 Apr 2023.
5. US Food and Drug Administration. Postmarketing surveillance programs. 2020. https://www.fda.gov/drugs/surveillance/postmarketing-surveillance-programs. Accessed 13 Apr 2023.